Cquence colorectal cancer mutation panel
Are you a medical professional?

What is the test for?

Cquence colorectal genotyping panel provides hopes for recovery and improves quality of life for patients with colorectal cancer. Colorectal cancer, or CRC, refers to the development of cancer in the large intestine (colon or rectum in particular). It is the second most prevalent cancer in Hong Kong, with over 4000 new cases annually, killing approximately 20001.

How does this test help treat colorectal cancer?

This test enables doctors in determining the best medication for colorectal cancer. Cquence colorectal genotyping panel is a precision medical test designed to determine and categorize the top 3 genes related to colorectal cancer: KRAS, BRAF and NRAS. Finding out these cancer genes is important in making decisions and predicting responses for targeted-therapies and/or other treatments specific for the patient tested.

What are cancer genes and how are they related to colorectal cancer?

KRAS, BRAF and NRAS are the known genes that cause resistance to EGFR-targeted therapies, which are commonly used for treating colorectal cancers2-3. Recent studies showed that BRAF mutation can even significantly worsen colorectal cancer4.

Who should consider this test?

Patients who are suffering from CRC and/or patients who have received targeted therapy and failed to show signs of recovery are advised to perform this test. 

How are samples obtained?

“Biopsy” is the surgical process which the doctor collects a section of suspected cancer tissue and sends it to the laboratory for analysis.

Test Specifications

Test Code
Specimen Requirements
Turnaround Time
Next generation sequencing (NGS)
10 FFPE unstained sections (6 um) with at least 20% tumor content 10 FFPE
17 days

What should I do if my test results are positive?

Please consult your physicians for professional advices.

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor
  1. http://www3.ha.org.hk/cancereg/statistics.html
  2. Douillard, Jean-Yves, et al. "Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer." New England Journal of Medicine 369.11 (2013): 1023-1034.
  3. Schwartzberg, Lee S., et al. "PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer." Journal of Clinical Oncology (2014): JCO-2013.
  4. Lochhead, Paul, et al. "Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication." Journal of the National Cancer Institute (2013): djt173.